Theravance Biopharma, Inc.
TBPH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$56,418 | -$55,193 | -$92,824 | -$265,071 |
| Dep. & Amort. | $3,615 | $4,256 | $7,024 | $8,598 |
| Deferred Tax | -$7,573 | $3,207 | $0 | $0 |
| Stock-Based Comp. | $21,393 | $25,371 | $39,734 | $62,061 |
| Change in WC | $20,355 | -$8,340 | $42,350 | -$39,549 |
| Other Non-Cash | $7,093 | $3,702 | -$183,275 | $26,103 |
| Operating Cash Flow | -$11,535 | -$26,997 | -$186,991 | -$207,858 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$332 | -$2,488 | -$572 | -$3,406 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$143,035 | -$134,534 | -$103,145 | -$158,305 |
| Inv. Sales/Matur. | $155,651 | $102,812 | $158,017 | $286,199 |
| Other Inv. Act. | $0 | $1,513 | $1,099,709 | $6 |
| Investing Cash Flow | $12,284 | -$32,697 | $1,154,009 | $124,494 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | -$631,603 | -$10,730 |
| Stock Issued | $99 | $0 | $0 | $108,180 |
| Stock Repurch. | -$3,104 | -$199,551 | -$132,280 | -$9,061 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $508 | $618 | $5,077 | $3,471 |
| Financing Cash Flow | -$2,497 | -$198,933 | -$758,806 | $91,860 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$1,748 | -$258,627 | $208,212 | $8,496 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $40,381 | $299,008 | $90,796 | $82,300 |
| End Cash | $38,633 | $40,381 | $299,008 | $90,796 |
| Free Cash Flow | -$11,867 | -$29,485 | -$187,563 | -$211,264 |